Teneligliptin hydrobromide hydrate is a dipeptidyl peptidase-4 (DPP-4) inhibitor primarily indicated for the management of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, this agent enhances… Read more
Teneligliptin hydrobromide hydrate is a dipeptidyl peptidase-4 (DPP-4) inhibitor primarily indicated for the management of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, this agent enhances incretin activity, which helps regulate blood glucose levels. To ensure the safety and efficacy of this medication, laboratories utilize high-quality reference standards for comprehensive quality control and analytical method validation. This category provides access to the active pharmaceutical ingredient, alongside related impurities, chiral isomers such as the R-isomer, and stable isotope-labelled compounds. These critical materials are essential for impurity profiling, allowing researchers to accurately detect, identify, and quantify impurities throughout the drug development and manufacturing process. By incorporating these analytical tools into testing protocols, pharmaceutical scientists can maintain rigorous regulatory compliance and uphold the highest standards of drug purity and consistency.
